1
|
Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 2021; 6:100328. [PMID: 34896698 PMCID: PMC8666642 DOI: 10.1016/j.esmoop.2021.100328] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 11/03/2021] [Accepted: 11/04/2021] [Indexed: 11/17/2022] Open
Abstract
Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care.
Collapse
Affiliation(s)
- J Tabernero
- Medical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), UVIC-UCC, IOB-Quiron, Barcelona, Spain.
| | - L Velez
- Medical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), UVIC-UCC, IOB-Quiron, Barcelona, Spain
| | - T L Trevino
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
| | - A Grothey
- West Cancer Center and Research Institute, OneOncology, Germantown, USA
| | - R Yaeger
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - E Van Cutsem
- Digestive Oncology Department, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium
| | - H Wasan
- Department of Cancer Medicine, Hammersmith Hospital, London, UK
| | - J Desai
- Department of Medical Oncology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Walter and Aliza Hall Institute, Parkville, Australia
| | - F Ciardiello
- Department of Precision Medicine, University of Campania, Naples, Italy
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | | | - S Kopetz
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
| |
Collapse
|
2
|
Velez L, Trevino T, Kopetz S, Grothey A, Yaeger R, Gollerkeri A, Maharry K, Tabernero J. SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Grothey A, Kopetz S, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Maharry K, Christy-Bittel J, Gollerkeri A, Tabernero J. LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.484] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren T, Arkenau HT, García-Alfonso P, Gollerkeri A, Pickard M, Maharry K, Christy-Bittel J, Anderson L, Kopetz S. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, García Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz183.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Van Cutsem E, Cuyle P, Huijberts S, Schellens J, Elez E, Yaeger R, Fakih M, Montagut C, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan H, Maharry K, Christy-Bittel J, Gollerkeri A, Kopetz S, Grothey A, Tabernero J. BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Huijberts S, Schellens J, Elez E, Cuyle PJ, Van Cutsem E, Yaeger R, Fakih M, Montagut C, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan H, Grothey A, Maharry K, Gollerkeri A, Kopetz S. BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Mendelson DS, Rosen LS, Gordon MS, Goldman JW, Olszanski AJ, Dai H, Perea R, Gollerkeri A. First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3055] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Rosen LS, Mendelson DS, Cohen RB, Gordon MS, Goldman JW, Bear IK, Byrnes B, Perea R, Schoenfeld SL, Gollerkeri A. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2524] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Coutre S, Martinelli G, Dombret H, Hochhaus A, Larson R, Saglio G, Gollerkeri A, Apanovitch A, Ottman OG. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 ‘START-L’ study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6528] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6528 Background: Dasatinib (D) (BMS-354825) is a multi-targeted kinase inhibitor of BCR-ABL and SRC. Preliminary data from a phase I study suggest high efficacy of D in IM pretreated pts. Methods: START L is an open label phase II study of D in IM-R or IM-I pts with LB-CML and Ph+ALL conducted at 42 centers worldwide. D was given orally, 70 mg twice a day (bid), with escalation to 100 mg bid for poor response or reductions to 50 mg and 40 mg bid for toxicity. Pts had weekly blood counts and monthly bone marrow exams, including cytogenetics. The primary endpoint was confirmed (sustained for at least 4 weeks) major hematologic response (MaHR) rates. Results: From January to June 2005, 101 pts were accrued. Data are available on the first 78 treated pts (42 LB-CML, 36 Ph+ALL). Of the 42 LB-CML pts, 37 were IM-R, 52% were male with median (med) age of 47 years. Prior therapy included IM >600 mg/day in 52% and stem-cell transplant (SCT) in 33% of pts. Med baseline platelet (plt) count was 32.5/nl, med BM blasts were 82%, Bcr-Abl mutations were seen in 48%, and extramedullary disease (EMD) was seen in 29% of pts. The D dose was reduced in 14%, temporarily interrupted in 33%, and escalated in 26% of pts. At 6-months, the MaHR rate was 31% including 26% complete hematologic response (CHR), the MCyR rate was 50%, and 17% of pts remained on study. Of the 36 Ph+ALL pts, 34 were IM-R, 64% were male with med age 46 years. Prior therapy included IM> 600 mg/day in 47% and SCT in 42% of pts. Baseline plt count was 53.5/nl, med BM blasts were 69%, Bcr-Abl mutations were seen in 47% and EMD was seen in 31% of pts. The D dose was reduced in 28%, temporarily interrupted in 39%, and escalated in 47% of the pts. At 6-months, the MaHR rate was 42% including 31% CHR, the MCyR rate was 58%, and 33% pts remained on study. Among all 78 pts, grade 3–4 thrombocytopenia and neutropenia was seen in 82% and 76% of pts, respectively. The most frequent D-related non-hematologic toxicities were diarrhea (30%), nausea (23%), fatigue (19%), rash (17%) and pleural effusion (13%). Conclusions: D is active in IM pretreated LB-CML and Ph+ALL pts. Data on all 101 pts will be presented at the meeting. [Table: see text]
Collapse
Affiliation(s)
- S. Coutre
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - G. Martinelli
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - H. Dombret
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - A. Hochhaus
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - R. Larson
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - G. Saglio
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - A. Gollerkeri
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - A. Apanovitch
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| | - O. G. Ottman
- Stanford University School of Medicine, Stanford, CA; Universita’ di Bologna, Bologna, Italy; Centre Hospitalier, Paris, France; Klinische Medizin Mannheim, Mannheim, Germany; University of Chicago, Chicago, IL; Azienda Ospedaliera S. Luigi, Orbassano, Italy; Bristol-Myers Squibb, Wallingford, CT; Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
| |
Collapse
|
11
|
Petrilli AS, Jakacki RI, Perek D, Quintana J, Garami M, Hussein H, Gore L, Messina M, Gollerkeri A. Randomized phase II study of carboplatin and irinotecan or irinotecan in 1–21 year old patients with refractory solid tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. S. Petrilli
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - R. I. Jakacki
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - D. Perek
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - J. Quintana
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - M. Garami
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - H. Hussein
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - L. Gore
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - M. Messina
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| | - A. Gollerkeri
- Instituto de Oncologia Pediatrica - GRAACC/UNIFESP-EPM, Sao Paulo, SP, Brazil; Children's Hospital of Pittsburgh, Pittsburgh, PA; Children's Memorial Health Institute, Warszawa, Poland; Clinica Oncologica LTDA, Santiago, Chile; Semmelweis University, Budapest, Hungary; Tanta Cancer Center, Tanta, Egypt; University of Colorado Health Sciences, Denver, CO; Bristol-Myers Squibb, Wallingford, CT
| |
Collapse
|
12
|
Schmitz JC, Liu J, Lin X, Chen TM, Yan W, Tai N, Gollerkeri A, Chu E. Translational regulation as a novel mechanism for the development of cellular drug resistance. Cancer Metastasis Rev 2002; 20:33-41. [PMID: 11831645 DOI: 10.1023/a:1013100306315] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Cellular drug resistance is one of the principal obstacles to the clinical efficacy of cancer chemotherapy. In this review, we describe the potential role for translational regulation as a novel mechanism for modulating chemosensitivity. The evidence for the translational control of thymidylate synthase, dihydrofolate reductase, and p53 will be presented, as will experimental data showing how disruptions in this important regulatory process can lead to the rapid emergence of cellular drug resistance.
Collapse
Affiliation(s)
- J C Schmitz
- Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA CT Cancer Center, VA CT Healthcare System, New Haven 06516, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int J Cancer 2001. [PMID: 11391633 DOI: 10.1002/ijc.1295.(] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Cardiac toxicity is frequently the indication for discontinuation of an anthracycline in patients with tumors which remain anthracycline-sensitive. During the 1990s, the most frequently used second-line agents at the Yale Cancer Center (YCC) were the taxanes. The goal of this retrospective analysis was to determine the effect of paclitaxel on cardiac function in patients with cardiomyopathy. YCC outpatient clinic pharmacy order forms were used to identify all patients who had received paclitaxel between December 1995 and November 1997. The clinic records of those patients with a left ventricular ejection fraction (LVEF) of < or = 50% were reviewed to determine the temporal relation between the decreased LVEF and paclitaxel therapy. In addition, clinic records were examined for evidence of prior doxorubicin therapy and history of prior cardiac disease. Between December 1995 and November 1997, 225 patients were treated with paclitaxel in the YCC outpatient clinic. Nine patients had LVEF < or = 50% (mean 37%) prior to initiation of paclitaxel therapy. Six of these patients had equilibrium radionuclide angiocardiographic (ERNA) scans following completion of paclitaxel. In these 6 patients, the mean change in LVEF was +6% (range -3% to +29%). Four patients had improved LVEF following paclitaxel (mean 11%, range 2% to 29%), while 2 patients experienced a decrease in LVEF following paclitaxel treatment (mean 2.5%). The 3 patients who did not have ERNA scans following paclitaxel therapy had no clinical evidence of congestive heart failure. Our experience confirms the results of prior studies that paclitaxel can be safely administered in patients with underlying cardiac dysfunction.
Collapse
Affiliation(s)
- A Gollerkeri
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | |
Collapse
|
14
|
Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int J Cancer 2001; 93:139-41. [PMID: 11391633 DOI: 10.1002/ijc.1295] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Cardiac toxicity is frequently the indication for discontinuation of an anthracycline in patients with tumors which remain anthracycline-sensitive. During the 1990s, the most frequently used second-line agents at the Yale Cancer Center (YCC) were the taxanes. The goal of this retrospective analysis was to determine the effect of paclitaxel on cardiac function in patients with cardiomyopathy. YCC outpatient clinic pharmacy order forms were used to identify all patients who had received paclitaxel between December 1995 and November 1997. The clinic records of those patients with a left ventricular ejection fraction (LVEF) of < or = 50% were reviewed to determine the temporal relation between the decreased LVEF and paclitaxel therapy. In addition, clinic records were examined for evidence of prior doxorubicin therapy and history of prior cardiac disease. Between December 1995 and November 1997, 225 patients were treated with paclitaxel in the YCC outpatient clinic. Nine patients had LVEF < or = 50% (mean 37%) prior to initiation of paclitaxel therapy. Six of these patients had equilibrium radionuclide angiocardiographic (ERNA) scans following completion of paclitaxel. In these 6 patients, the mean change in LVEF was +6% (range -3% to +29%). Four patients had improved LVEF following paclitaxel (mean 11%, range 2% to 29%), while 2 patients experienced a decrease in LVEF following paclitaxel treatment (mean 2.5%). The 3 patients who did not have ERNA scans following paclitaxel therapy had no clinical evidence of congestive heart failure. Our experience confirms the results of prior studies that paclitaxel can be safely administered in patients with underlying cardiac dysfunction.
Collapse
Affiliation(s)
- A Gollerkeri
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | |
Collapse
|
15
|
Rose M, Lee FA, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness BA. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplant 2000; 26:133-9. [PMID: 10918422 DOI: 10.1038/sj.bmt.1702449] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Breast cancer patients with cardiac disease are usually excluded from clinical trials of high-dose chemotherapy. We treated 52 patients with inflammatory and/or metastatic disease with sequential high-dose melphalan and stem cell rescue followed by high-dose thiotepa and stem cell rescue. Stem cells were mobilized with cyclophosphamide and/or paclitaxel and filgrastim. Left ventricular ejection fraction (LVEF) was measured by equilibrium radionuclide angiocardiography (ERNA) at baseline, after each course of chemotherapy and 4 weeks after completing both transplants. The mean absolute decrease in LVEF after the two transplants was 3.6% (P = 0. 008 for the comparison with baseline LVEF), and most of this drop (-2.5%, P = 0.007) occurred after mobilization. Unexpectedly, paclitaxel was associated with a mean absolute decrease in LVEF of 3. 4% (P = 0.032, n = 19), cyclophosphamide alone was not associated with a significant change in LVEF (-1.3%, P = 0.23), but mobilization with sequential paclitaxel and cyclophosphamide resulted in a mean absolute drop of 4.9% in LVEF (P = 0.009). Twelve patients were found to have a reduced LVEF (<50%) at least once during treatment and had a mean absolute decrease in LVEF of 10% (P = 0.008) from baseline, compared with a drop of only 1.8% (P = 0. 176) in the patients without impaired LV function. Although two of these 12 patients developed symptomatic heart failure, their cardiac symptoms were easily treated and there were no cardiac deaths. We conclude that our protocol has acceptable cardiac toxicity and breast cancer patients with impaired LV function should not be denied high-dose chemotherapy if otherwise indicated.
Collapse
Affiliation(s)
- M Rose
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Murren JR, Gollerkeri A, Anderson S, Lutzker S, Del Prete S, Zelterman D, Garrison L, Smith B. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen. Yale J Biol Med 1998; 71:355-65. [PMID: 10527363 PMCID: PMC2578930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE Treatment with hematopoietic growth factors increases the percentage of hematopoietic progenitor cells in cell cycle. Following withdrawal of certain growth factors, preclinical data suggest that there is a transient fall in the percentage of progenitor cells in cycle below the baseline, thus providing a window to administer chemotherapy with reduced risk of myelotoxicity. PATIENTS AND METHODS Patients with histologically confirmed, previously untreated neoplasia, were treated with pIXY321 by subcutaneous injection at a dose of 375 microg/m2 twice daily (total dose 750 microg/m2/day) for seven days (days -8 to -2), followed by a two-day rest (days -1 to 0). Patients received ICE (ifosfamide, carboplatin and etoposide) on days 1 to 3. On day 4, pIXY321 was resumed until hematologic recovery. Peripheral blood was collected on days -8, -2, -1, 1, and cell cycle distribution was determined using flow cytometry. RESULTS Twenty patients were treated in this study and received a total of 54 cycles. Partial responses were observed in three of 13 patients with non-small cell lung cancer (23 percent) and two of five patients with small cell lung cancer (40 percent). Six of 15 patients had an increased number of cells in S+G2/M on day 1 of ICE following seven days of pIXY321 and two days off (days -1 to 0). The average increase was 63 percent (range 6-253). Seven patients had a decreased number of cells in S+G2/M. The average decrease was 55 percent (range 6.3-78). There were no significant differences among the fifteen patients with regards to the observed toxicity of the chemotherapy. DISCUSSION pIXY321 in this schedule did not consistently decrease the percentage of cycling progenitor cells in the peripheral blood. Future studies should define whether other growth factors and/or schedules can synchronize progenitor cell cycling and protect the marrow compartment from cycle specific chemotherapy.
Collapse
Affiliation(s)
- J R Murren
- Yale University School of Medicine and the Yale Cancer Center, New Haven, Connecticut 06520, USA.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, Cole B, Myers J, Tarpey J, Rosmarin A. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 1996; 78:1203-10. [PMID: 8826941 DOI: 10.1002/(sici)1097-0142(19960915)78:6<1203::aid-cncr6>3.0.co;2-a] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Mutations in the tumor suppressor gene p53 have been associated with resistance to ionizing radiation and chemotherapy. Paclitaxel and concurrent radiation (paclitaxel/RT) achieve high response rates with locally advanced nonsmall cell lung carcinoma (NSCLC). In vitro data and animal studies suggest that paclitaxel may have a unique ability to activate tumor cell apoptosis in the absence of wild-type p53 function. The authors sought to determine whether p53 mutations affect response to paclitaxel/RT in patients with locally advanced NSCLC. METHODS Thirty patients with Stage IIIA or IIIB NSCLC who participated in Brown University Oncology Group protocols utilizing paclitaxel/RT had tumor tissue that was adequate for analysis. Mutations were detected in tumor tissue by single-strand conformation polymorphism analysis of exons 5 through 8 of the p53 gene, and confirmed by direct sequencing. RESULTS Mutations in p53 were found in 12 of 30 patients (40%). The response rates (complete plus partial) of 75% for patients with tumors with p53 mutations, and 83% for patients with wild-type p53, did not differ significantly (P = 0.70). CONCLUSIONS p53 mutations do not predict response of patients with NSCLC to paclitaxel/RT. This finding is in striking contrast to results with other chemotherapeutic agents and ionizing radiation. These clinical data support in vitro data and animal studies regarding the unique mechanism of the action of paclitaxel. Further investigation is needed to determine the mechanism of lung tumor cell death after paclitaxel/RT. These results suggest that paclitaxel/RT may be an active regimen for patients with other locally advanced neoplasms with high rates of p53 gene mutations.
Collapse
Affiliation(s)
- H Safran
- Department of Medicine, Brown University, Miriam Hospital, Providence, Rhode Island 02906, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Ramratnam B, Gollerkeri A, Martens P, Schiffman FJ, Parameswaran J. A study of cross-coverage calls. J Gen Intern Med 1996; 11:189. [PMID: 8667101 DOI: 10.1007/bf02600277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|
19
|
Abstract
An HIV+ 26-year-old white man with a CD4 count of 0.06 x 10(9)/l was found to have red blood cell aplasia secondary to B19 parvovirus infection. Regular infusions of intravenous immunoglobulin (IVIG) were begun and resulted in marked reticulocytosis and correction of anaemia. The patient has been followed for over 4 years and has become anaemic and reticulocytopenic whenever IVIG was interrupted. Serial dot blot analysis of the patient's sera for B19 parvovirus DNA showed absence of DNA immediately following IVIG treatments but reappearance within 3-6 weeks. Regular IVIG was effective in controlling but not eradicating B19 parvovirus infection in this HIV+ patient.
Collapse
Affiliation(s)
- B Ramratnam
- Department of Medicine, Miriam Hospital, Brown University School of Medicine, Providence, Rhode Island, USA
| | | | | | | | | |
Collapse
|